ONCOLOGY Decoded

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD

May 1st 2025

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Episode 5: Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD

May 1st 2025

Panelists discuss how the evolving landscape of adjuvant therapy in kidney cancer, including targeted therapies and immunotherapy like pembrolizumab, offers curative potential for high-risk patients, with a focus on risk stratification, treatment sequencing, and managing recurrence while weighing benefits and toxicities.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD

April 1st 2025

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD

April 1st 2025

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,Stephanie A. Berg, DO

March 7th 2025

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

ByManojkumar Bupathi, MD, MS,Ben Garmezy, MD,Stephanie A. Berg, DO

March 7th 2025

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,David Morris, MD, MS,Tanya B. Dorff, MD,Mark T. Fleming, MD

March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

ByManojkumar Bupathi, MD, MS,Ben Garmezy, MD,David Morris, MD, MS,Tanya B. Dorff, MD,Mark T. Fleming, MD

March 5th 2025

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

ByManojkumar Bupathi, MD, MS,Benjamin Garmezy, MD,Petros Grivas, MD, PhD,David Morris, MD, MS

March 4th 2025

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Episode 1: NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

ByManojkumar Bupathi, MD, MS,Ben Garmezy, MD,Petros Grivas, MD, PhD,David Morris, MD, MS

March 4th 2025

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.